Skip to main content
Laboratorio Farmaceutico Erfo logo

Laboratorio Farmaceutico Erfo — Investor Relations & Filings

Ticker · ERFO ISIN · IT0005497885 LEI · 8945005CB564D0OBQQ85 XMIL Manufacturing
Open in API
Filings indexed 127 across all filing types
Latest filing 2026-02-19 Earnings Release
Country IT Italy
Listing XMIL ERFO

About Laboratorio Farmaceutico Erfo

https://www.erfo.it/

Laboratorio Farmaceutico Erfo S.p.A. specializes in the formulation, production, and marketing of nutraceutical products and food supplements. The company operates a multi-brand wellness ecosystem through a network of specialized centers. Its primary brand, Diètnatural, provides nutritional path services across more than 120 locations. The portfolio also includes BodySano, which focuses on nutrition and advanced aesthetics in French-speaking markets, and Fit&Go, a network of over 100 high-tech and fast-fitness centers. This integrated model combines the company's supplement products with personalized wellness, aesthetic, and fitness services delivered through its franchise networks.

Recent filings

Filing Released Lang Actions
Laboratorio Farmaceutico Erfo S.p.A. - Comunicazione dati gestionali FY 2025
Earnings Release Classification · 100% confidence The document is a press release from Laboratorio Farmaceutico Erfo S.p.A. announcing consolidated financial data (revenues, EBITDA, NFP) for the fiscal year ending December 31, 2025. It provides key highlights and management commentary on performance, which is characteristic of an Earnings Release. It is not a full annual report (10-K) as it explicitly states the data is 'not subject to statutory audit' and is presented in a press release format. FY 2025
2026-02-19 Italian
Laboratorio Farmaceutico Erfo S.p.A. - Informativa settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is a weekly press release from Laboratorio Farmaceutico Erfo S.p.A. detailing the purchase of its own shares (buyback) during the period from February 2 to February 7, 2026. It provides specific data on the number of shares purchased, the average price, and the total value, which aligns perfectly with the definition of 'Transaction in Own Shares' (POS).
2026-02-07 Italian
Laboratorio Farmaceutico Erfo S.p.A. - Risoluzione dell'incarico di specialist e conferimento nuovo incarico
Regulatory Filings Classification · 95% confidence The document is a press release from Laboratorio Farmaceutico Erfo S.p.A. announcing the change of its 'Specialist' (a market maker role on the Euronext Growth Milan exchange). The document is short (under 5,000 characters), serves as a formal regulatory announcement regarding corporate operations, and does not fit into specific categories like M&A, financial reports, or director dealings. Therefore, it is classified as a general regulatory filing.
2026-02-03 Italian
Laboratorio Farmaceutico Erfo S.p.A. - Informativa settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is a press release from Laboratorio Farmaceutico Erfo S.p.A. titled 'Informativa settimanale in merito al piano di acquisto azioni proprie' (Weekly report regarding the share buyback plan). It details the specific number of shares purchased, the average price, and the total value of the transaction for the period of January 26-30, 2026. This falls directly under the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2026-01-31 Italian
Laboratorio Farmaceutico Erfo - Comunicazione internal dealing
Director's Dealing Classification · 100% confidence The document is a standard 'Internal Dealing' notification form, which is used to report transactions by persons discharging managerial responsibilities (PDMRs) or their closely associated persons. This corresponds to the 'Director's Dealing' category, which covers insider trades and transactions by company executives or their associated entities.
2025-12-16 Italian
Laboratorio Farmaceutico Erfo S.p.A. - Comunicazione dati gestionali IIIQ 2025
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated November 21, 2025, from Laboratorio Farmaceutico Erfo S.p.A., providing consolidated economic and financial management data as of September 30, 2025. It includes detailed financial figures such as consolidated revenues, EBITDA, EBITDA margin, and net financial position, along with business updates and strategic commentary from the CEO. The data is explicitly stated as not subject to audit and is described as 'dati gestionali economico-finanziari consolidati' (consolidated economic-financial management data). The document is lengthy (15,000 characters) and contains substantive financial data and analysis for a period shorter than a full fiscal year (the first nine months of 2025). It is not a full annual report (10-K), nor is it a simple announcement or certification. It is a comprehensive interim/quarterly financial report with management commentary and financial metrics. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2025
2025-11-21 Italian

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.